Filing Flows › Roivant Sciences (ROIV) › Q2 FY27
Roivant Sciences (ROIV) Q2 FY27 earnings results (second quarter fiscal 2027)
10-Q filed Nov 9, 2026
Roivant Sciences (ROIV) reported revenue of $35.1M for the second quarter fiscal 2027 (Q2 FY27), up 22-fold from a year earlier and up 24-fold from the quarter before. Operating margin was -763.2%, net loss $137M (390.7% of revenue).
Roivant Sciences, Q2 FY27: revenue $35.1M (22× year over year), operating margin -763.2%, net loss $137M, operating cash flow $594M. The chart follows the revenue to costs, profit and cash.
| Q2 FY27 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $35.1M | 24× | 22× |
| Operating profit | −$268M | — | — |
| Net earnings | −$137M | — | — |
| Operating cash flow | $594M | — | — |
| Free cash flow | $594M | — | — |
What changed
Revenue was $35.1M in Q2 FY27, up 2136% year over year and up 2336% from the previous quarter. Product revenue, net was the largest line at 88% of revenue. License, milestone and other revenue added $2.6M year over year (up 164%), 8% of the total change.
Operating costs exceeded revenue by $268.0M, an operating margin of -763.2%. Total costs fell 2% while revenue rose 2136%. The fastest-growing cost line was Cost of revenue (+2915%). The quarter ended with a net loss of $137.2M, narrower than the previous quarter's $290.6M loss. Non-operating items added $117.5M, so the bottom line overstates operating performance.
Operating cash flow was $594.4M. Non-cash charges added back $604K of depreciation and amortization and $79.3M of share-based compensation. Working capital and other items added $651.7M. Capital expenditures of $208K left free cash flow of $594.2M.
Questions
What was Roivant Sciences' revenue in the second quarter fiscal 2027?
Roivant Sciences (ROIV) reported revenue of $35.1M for the second quarter fiscal 2027 (Q2 FY27), up 22-fold from a year earlier and up 24-fold from the quarter before.
Was Roivant Sciences profitable in the second quarter fiscal 2027?
Operating loss was $268M (-763.2% of revenue) and net loss $137M.
Source: Roivant Sciences 10-Q on SEC EDGAR.